Compare Google Inc (GOOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs BIO-TECHNE Corp — how do they compare? Google Inc trades at $346.34 (market cap $4.27T), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Google Inc is far larger — about 375.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and BIO-TECHNE Corp for 63 Days on average.
| GOOG | TECH | |
|---|---|---|
Market Cap | $4.27T | $11.37B |
Volume | 11,294,477 | 3,153,511 |
Sector | Media | Health |
52-Week High | $399.06 | $72.61 |
52-Week Low | $237.49 | $43.31 |
Typical Hold Time | 137 Days | 63 Days |
Enterprise Value | $4.16T | $11.40B |
Dividend Yield | 0.25% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, up 0.08% on the day, with a bullish technical signal from moving averages and strong analyst support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $9.11 versus $2.87 expected. Revenue growth remains robust, climbing to $402.84 billion in 2025, while profitability metrics like a 54.77% net income margin and 49.55% ROE highlight operational efficiency.
The stock offers significant upside to the consensus price target of $431.41, but risks include rising capital expenditures leading to negative free cash flow projections and ongoing securities litigation. Investor sentiment is positive due to AI-driven cloud growth, though regulatory scrutiny and competitive pressures persist.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
